NEWS
Novel cell analyser features breakthrough technologies
Becton Dickinson (BD) has announced the global commercial launch of the world’s first cell analyser featuring breakthrough spectral and real-time cell imaging technologies.
BD says the new FACSDiscover A8 Cell Analyzer will enable more researchers across a wider range of applications to uncover deeper insights and dynamics from cells once invisible in flow cytometry experiments – with increased ease and throughput.
The company’s SpectralFX technology maximises the number of colours that can be used in flow cytometry, allowing scientists to analyse up to 50 or more characteristics of a single cell at one time, with optimal resolution and sensitivity, which is ideal for scientists pursuing novel biomarker discovery. BD CellView image technology enables high-speed fluorescent and label-free imaging of single cells, revealing precise spatial and morphological insights – like the location of a virus or protein within a single cell, or the microscopic interaction between two cells – that can be visually confirmed and analysed in real time.
Combining these technologies,
which were first introduced in the BD FACSDiscover S8 Cell Sorter and profiled on the cover of the journal Science, the BD FACSDiscover A8 Cell Analyzer enables scientists to capture more insights per experiment than ever, with exceptional depth, speed and sensitivity. New software innovations launching alongside the instrument include the latest version of BD FACSChorus Software, which simplifies workflows on both the BD FACSDiscover A8 Cell Analyzer as well as FACSDiscover S8 Cell Sorter, and the faster, easier-to-use analysis software FlowJo v11.
Improving blood culture diagnostics across the NHS
IBMS, BD and PLMR Healthcomms have released a new report which highlights the need for more consistent and collaborative approaches to reduce contamination rates, improve diagnostic accuracy and enhance patient care.
Based on national FOI data and in-depth interviews, the new paper, Lost in the Bloodstream – A Holistic Approach to Blood Culture Improvement, brings together the experiences and insights of NHS professionals across the blood culture pathway. Blood culture tests are a critical part of diagnosing bloodstream infections. However, delays, variation in practice, and high contamination rates can lead to misdiagnosis, inappropriate treatment and increased patient risk.
Drawing on the experiences of NHS clinical leaders and pathology professionals, the report outlines a series of interventions to improve performance across the full pathway – from test ordering and sample collection to laboratory analysis and clinical communication. David Wells, Chief Executive of the IBMS,
said: “Blood culture testing is a vital part of infection diagnosis, the timely delivery of blood cultures saves lives and improves AMR stewardship. Improving the pathway requires not just technical solutions but system-wide collaboration – from the ward to the laboratory. This report highlights how better practice and joined-up working can protect patients and support clinical teams.” The full report can be downloaded from the IBMS website
www.IBMS.org.
EUROIMMUN unveils IDS i20 platform
Revvity has announced the launch of its new IDS i20 analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked, and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reagent capacity and higher test throughput compared to existing offerings.
The highly versatile IDS i20 instrument allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. These specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer’s disease and therapeutic drug monitoring. While specialty assays in these diagnostic areas tend to be processed manually or with semi-automated, low- throughput analysers, the IDS i20 platform offers laboratories a new means of more flexible, fully automated ChLIA processing. With the ability to process up to 140 tests per hour (assay dependent), the IDS i20 instrument is the latest addition to the
12
well-established IDS i-device series, built on more than 50 years of experience in medical device design and innovation. The IDS i20 platform features new
software offering a high degree of adaptability and scalability, along with a graphical user interface that meets the latest standards of ergonomics, usability and cybersecurity. Continuous loading of samples and reagents as well as the integrated cooling of ready-to-use reagent cartridges allow for non-stop operation of the system – maximising efficiency and minimising hands-on time.
JUNE 2025
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
